Fig. 5

Apatinib suppressed the β-catenin pathway via VEGFR2/Akt/GSK-3β. a KYSE30 cells were exposed to apatinib (3, 10 and 30 μM) for 24 h. The protein levels of Akt, p-Akt, GSK-3β, p-GSK-3β and β-catenin were detected by western blotting. KYSE30 cells were pretreated with DMSO or SC79 (5 μM) and then exposed to apatinib (10 μM) for 24 h. b The protein levels of p-Akt and β-catenin were detected by western blotting. c The mRNA expression levels of Myc and Jun were examined by qPCR. P values were determined by Student’s t test. **P < 0.01. d The transcriptional activity was detected by luciferase reporter assays. P values were determined by Student’s t test. **P < 0.01. KYSE30 cells were pretreated with DMSO or SC79 (5 μM) and then exposed to apatinib (30 μM) for 24 h. e Cell viability of KYSE30 cell line detected by a CCK-8 kit. P values were determined by Student’s t test. **P < 0.01. f Apoptosis was determined by flow cytometry. P values were determined by Student’s t test. **P < 0.01. Data are representative of three independent experiments (mean and SEM in c–f)